Investigation of potential additive inhibitory effects on HPA [hypothalamic pituitary adrenal]-axis of ciclesonide nasal spray when administered concomitantly with orally inhaled beclomethasone dipropionate [beclomethasone] (HFA [hydrofluoroalkane] -BDP) in patients (18-60 years) with perennial allergic rhinitis (PAR)

Trial Profile

Investigation of potential additive inhibitory effects on HPA [hypothalamic pituitary adrenal]-axis of ciclesonide nasal spray when administered concomitantly with orally inhaled beclomethasone dipropionate [beclomethasone] (HFA [hydrofluoroalkane] -BDP) in patients (18-60 years) with perennial allergic rhinitis (PAR)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary) ; Beclometasone
  • Indications Perennial allergic rhinitis
  • Focus Pharmacokinetics; Registrational
  • Sponsors ALTANA Pharma
  • Most Recent Events

    • 04 May 2012 Company (Takeda Global Research and Development Center, Inc) added as reported by ClinicalTrials.gov.
    • 05 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top